Managing blood sugar side effects from inavolisib
Part of Cancer, Hormones & metabolism, Skin clinical trials.
This study looks at how to best manage high blood sugar, a common side effect of the drug inavolisib, in people with a certain type of breast cancer. It aims to help patients stay on their treatment and improve their quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of breast cancer that is hormone receptor-positive and HER2-negative, and has spread to nearby tissue or other parts of the body.
- Your tumor has a specific genetic change called PIK3CA, confirmed by a blood or tissue test.
- You are about to start inavolisib for the first time.
- Your hospital can provide your complete medical and prescription records.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines two or three drugs (inavolisib, fulvestrant, and sometimes palbociclib) to treat hormone receptor positive, HER2 negative advanced breast cancer that has a PIK3CA mutation. The goal is to find out if this combination is safe and effective for people who also have type 2 diabetes.
This study looks at how well a drug called inavolisib works when combined with hormone therapy for people with a certain type of advanced breast cancer that has a specific gene change (PIK3CA). It aims to see if this treatment helps control the cancer in real-world settings.
This study tests a new drug called inavolisib for people with early-stage breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding this drug to standard hormone therapy is safe and effective before surgery.
This trial tests whether a new targeted pill (inavolisib) plus hormone therapy (fulvestrant) can slow or stop breast cancer growth in people whose cancer has a specific genetic change called a PIK3CA mutation. It is for patients whose disease worsened after previous hormone-and-CDK-inhibitor treatment.
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
This trial tests whether a new drug combo (inavolisib plus fulvestrant) works better than an existing one (alpelisib plus fulvestrant) for people with a specific type of advanced breast cancer that has a PIK3CA mutation. It aims to find a treatment that may help control the cancer longer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.